Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMA · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| SGN-CD33A + HMA | EXPERIMENTAL | SGN-CD33A with hypomethylating agent |
| SGN-CD33A Monotherapy | EXPERIMENTAL | SGN-CD33A |
| Name | Type | Description |
|---|---|---|
| HMA | DRUG | azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days |
| SGN-CD33A | DRUG | Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA) |
Inclusion Criteria: * Acute myeloid leukemia, positive for CD33 * Eastern Cooperative Oncology Group status of 0 or 1 * Adequate baseline renal and hepatic function * Central venous access * Either achieved complete remission (greater than 12 weeks in duration) with initial induction/consolidation ...
HMA is an investigational small molecule being studied for the treatment of Acute Myelogenous Leukemia (AML). It is currently in Phase 1 clinical development. The drug is being evaluated in patients with AML, including related conditions such as Acute Myeloid Leukemia and Acute Promyelocytic Leukemia.
HMA is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for the treatment of Acute Myelogenous Leukemia.
HMA is in Phase 1 clinical development. It is an investigational drug being studied for the treatment of Acute Myelogenous Leukemia. The drug has completed one Phase 1 clinical trial and is not yet approved by regulatory authorities.
HMA has been studied in one completed Phase 1 clinical trial with the identifier NCT01902329. This trial, titled 'A Safety Study of SGN-CD33A in AML Patients', enrolled 195 participants with Acute Myelogenous Leukemia, Acute Myeloid Leukemia, and Acute Promyelocytic Leukemia. The trial was conducted in the United States.
HMA is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of Acute Myelogenous Leukemia. The drug has completed one Phase 1 clinical trial, but it has not yet received regulatory approval.